2. Cell Cycle/DNA Damage
  3. Polo-like Kinase (PLK)
  4. PLK1-IN-10

PLK1-IN-10 (Compound 4Bb) is an orally active PLK1 PBD (polo-box domain) inhibitor. PLK1-IN-10 blocks the interaction of PLK1 with the cell division regulator protein 1 (PRC1) and decreases the protein expression of the CDK1-Cyclin B1 complex. PLK1-IN-10 reacts with glutathione (GSH) to increase cellular oxidative stress, ultimately leading to cell death.

For research use only. We do not sell to patients.

CAS No. : 2991469-21-5

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

PLK1-IN-10 Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE PLK1-IN-10

WB

    PLK1-IN-10 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Jul 15;44(1):206.  [Abstract]

    Western blot analysis was used to detect the protein and phosphorylation levels of PRC1 in cells after treatment. H1299 cells were subcutaneously injected into nude mice to construct xenografts, followed by intratumoral injections (10 mg/kg: Bobcat339, HPPE, or PLK1-IN-10) starting from day 7.

    View All Polo-like Kinase (PLK) Isoform Specific Products:

    View All Isoforms
    PLK1 PLK2 PLK3 PLK4

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    PLK1-IN-10 (Compound 4Bb) is an orally active PLK1 PBD (polo-box domain) inhibitor. PLK1-IN-10 blocks the interaction of PLK1 with the cell division regulator protein 1 (PRC1) and decreases the protein expression of the CDK1-Cyclin B1 complex. PLK1-IN-10 reacts with glutathione (GSH) to increase cellular oxidative stress, ultimately leading to cell death[1].

    IC50 & Target

    PLK1 PBD

     

    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    10.56 μM
    Compound: 4Bb
    Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    		[PMID: 38657480]
    A549/CDDP IC50
    2.65 μM
    Compound: 4Bb
    Anticancer activity against human A549/DDP cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    Anticancer activity against human A549/DDP cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    		[PMID: 38657480]
    MCF7 IC50
    6.54 μM
    Compound: 4Bb
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    		[PMID: 38657480]
    MGC-803 IC50
    3.2 μM
    Compound: 4Bb
    Anticancer activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    Anticancer activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    		[PMID: 38657480]
    NCI-H460 IC50
    2.31 μM
    Compound: 4Bb
    Anticancer activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    Anticancer activity against human NCI-H460 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    		[PMID: 38657480]
    SK-OV-3 IC50
    2.84 μM
    Compound: 4Bb
    Anticancer activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    Anticancer activity against human SK-OV-3 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    		[PMID: 38657480]
    T-24 IC50
    2.9 μM
    Compound: 4Bb
    Anticancer activity against human T24 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    Anticancer activity against human T24 cells assessed as inhibition of cell growth incubated for 48 hrs by crystal violet staining based analysis
    		[PMID: 38657480]
    In Vitro

    PLK1-IN-10 (0-6 μM; 48 h) induces cell cycle arrest in the G2/M phase in A549 and A549/DDP cells, inhibiting cell proliferation[1].
    PLK1-IN-10 (20 μM) stabilizes PLK1 protein in A549/DDP cells across a range of temperatures[1].
    PLK1-IN-10 (5 μM; 24 h) reacts with GSH, producing a dose- and time-dependent fluorescent response, with higher fluorescence intensity in A549/DDP cells[1].
    PLK1-IN-10 (0-9 μM; 48 h) increases intracellular ROS levels in A549/DDP cells[1].
    PLK1-IN-10 (10 μM; 48 h) inhibits the interaction between PLK1 and PRC1, leading to the appearance of multinucleated cells[1].
    PLK1-IN-10 shows an anticancer activity of IC50=7.83 μM against NCI-H1975 cells[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    PLK1-IN-10 Related Antibodies

    Western Blot Analysis[1]

    Cell Line: A549, A549/DDP
    Concentration: 0, 1.5, 3, 6 μM
    Incubation Time: 48 h
    Result: Downregulated the expression of PLK1, CDK1, Cyclin B1, as well as significantly downregulated the expression of the CDK1-Cyclin B1 complex and Cdc25 protein.

    Cell Cycle Analysis[1]

    Cell Line: A549, A549/DDP
    Concentration: 0, 1.5, 3, 6 μM
    Incubation Time: 48 h
    Result: Significantly increased the number of A549 and A549/DDP cells in the G2/M phase, inducing mitotic catastrophe.
    In Vivo

    PLK1-IN-10 (30, 50 mg/kg; i.p.; every two days for 32 days) significantly inhibits tumor growth in A549/DDP drug-resistant xenograft mice, with the 50 mg/kg group even causing tumor regression[1].
    PLK1-IN-10 (30 mg/kg; p.o.; every two days for 20 days) effectively inhibits tumor growth in NCI-H1975 drug-resistant xenograft mice[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: A549/DDP drug-resistant xenograft mice[1]
    Dosage: 30, 50 mg/kg
    Administration: i.p.; once every two days for 32 days
    Result: TGI reached 42% for the 30 mg/kg group and 62% for the 50 mg/kg group.
    Extended the median survival time from 38 days in the control group to 53 days in the 30 mg/kg group and 62 days in the 50 mg/kg group.
    Had no significant impact on the body weight and major organs of the mice, except for a slight difference in heart index observed in the 30 mg/kg group.
    Significantly reduced the number of Ki-67 positive cells in the tumor tissue.
    Showed no significant differences in H&E staining of major organs, further confirming its good biosafety.
    Animal Model: NCI-H1975 drug-resistant xenograft mice[1]
    Dosage: 30 mg/kg
    Administration: p.o.; once every two days for 20 days
    Result: TGI reached 44%. Caused no harm to the body weight and major organs of the mice.
    Molecular Weight

    455.50

    Formula

    C23H22FN3O4S
    CAS No.
    SMILES

    CN(C)CCN(C1=O)C(C2=CC=C(S(NCC3=CC=C(F)C=C3)(=O)=O)C4=CC=CC1=C42)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Purity & Documentation
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    PLK1-IN-10 Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    PLK1-IN-102991469-21-5Polo-like Kinase (PLK)Drug resistanceMitotic catastropheCell redox homeostasiscancerCell Cycle ArrestGSH DepletionOxidative Stress InducerMitotic CatastropheInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    PLK1-IN-10
    Cat. No.:
    HY-161521
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.